Trexquant Investment LP Decreases Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Trexquant Investment LP lowered its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 24.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 442,018 shares of the biotechnology company's stock after selling 141,004 shares during the quarter. Trexquant Investment LP owned approximately 0.31% of Aurinia Pharmaceuticals worth $3,969,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Teacher Retirement System of Texas grew its position in Aurinia Pharmaceuticals by 5.9% during the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock worth $324,000 after acquiring an additional 2,020 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. boosted its position in Aurinia Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company's stock worth $273,000 after buying an additional 2,857 shares during the period. FMR LLC grew its holdings in Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock worth $93,000 after acquiring an additional 3,919 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 6,174 shares during the period. 36.83% of the stock is owned by institutional investors.

Remove Ads

Aurinia Pharmaceuticals Trading Down 5.6 %

Shares of NASDAQ:AUPH traded down $0.43 during midday trading on Thursday, reaching $7.19. The company's stock had a trading volume of 229,745 shares, compared to its average volume of 1,355,197. The firm has a 50 day moving average price of $8.04 and a two-hundred day moving average price of $8.09. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The firm has a market capitalization of $986.78 million, a price-to-earnings ratio of -48.09 and a beta of 1.20. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Insider Activity

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 8,305 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the transaction, the insider now directly owns 153,484 shares in the company, valued at $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at $15,631,136. This trade represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock worth $2,753,094 in the last quarter. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.